Trial Profile
A double-blind, placebo-controlled, single and multiple ascending dose phase I study to evaluate the safety, tolerability, and pharmacokinetics of CCX168 in healthy male and female subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Avacopan (Primary)
- Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Autoimmune disorders; Haemolytic uraemic syndrome; Hidradenitis suppurativa; IgA nephropathy; Membranoproliferative glomerulonephritis
- Focus Adverse reactions
- Sponsors ChemoCentryx
- 19 May 2016 New trial record